acetylcysteine/pentoxifylline (PTL 202) / IntelGenx, Nuon Therapeutics - LARVOL DELTA

Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. (PubMed, Med Hypotheses) - "When COVID-19 patients can be treated within several days of symptom onset, using PTX + DIP in conjunction with hydroxychloroquine (HCQ) and an antibiotic - azithromycin (AZM) or doxycycline - might be warranted...In contrast to HCQ, we propose that the combination of PTX + DIP can be used in both early and advanced stages of COVID-19. Concurrent use of certain nutraceuticals - yeast beta-glucan, zinc, vitamin D, spirulina, phase 2 inducers, N-acetylcysteine, glucosamine, quercetin, and magnesium - might also improve therapeutic outcomes in COVID-19."

Journal • Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumonia • Thrombosis

Role of oxidative stress and antioxidant supplementation in Male fertility. (PubMed, Curr Mol Med) - "Actually, anti-oxidants like vitamins E and C, glutathione, coenzyme-Q10, carnitines, selenium, N-acetylcysteine, carotenoids, zinc, and pentoxifylline decline the OS-induced sperm damages.Therefore, the present review overviews the oxidative bio-chemistry associated with the sperm health and identifies which men would be most at risk of the oxidative infertility. Hence, the re-view would show the techniques provided to diagnose OS and diverse therapeutic options."

Journal • Infertility • Sexual Disorders

The effects of anti-inflammatory agents as host-directed adjunct treatment of tuberculosis in humans: a systematic review and meta-analysis. (PubMed, Respir Res) - "Vitamin D and other anti-inflammatory HDT medications used as adjunct TB treatment may be well tolerated and effective. They significantly improved sputum smear conversion rate and chest radiological appearance, and also exhibited an inflammation resolution effect."

Journal • Retrospective data • Review • Immunology • Infectious Disease • Tuberculosis

Medical Treatment of Alcoholic Liver Disease (PubMed, Korean J Gastroenterol) - "Pentoxifylline is unlikely to affect short-term survival. Hence, studies on new therapies, such as granulocyte colony-stimulating factor and fecal microbiota transplantation, are ongoing. This paper briefly reviews the current knowledge of the medical treatment of alcoholic liver disease."

Journal • Review • Hepatology • Transplantation

The effects of specific and non-specific phosphodiesterase inhibitors and N-acetylcysteine on oxidative stress and remote organ injury in two-hit trauma model. (PubMed, Ulus Travma Acil Cerrahi Derg) - "This experimental study has shown that PDE inhibitors and NAS have a decreasing effect on oxidative stress and distant organ damage in the two-hit model. Further clinical and experimental studies are needed on this subject."

Journal • Immunology • Infectious Disease • Mood Disorders • Oncology • Septic Shock • Systemic Inflammatory Response Syndrome • CAT

Allowance by European Patent Office, of patent for PTL-202, a treatment for idiopathic pulmonary fibrosis, a $1.1 billion opportunity (Yahoo Finance) - "The Company is pleased to announce that the European Patent Office has issued an official letter stating that it intends to allow the application for the Company's patent COMPOSITIONS AND METHODS FOR TREATING FIBROPROLIFERATIVE DISORDERS."

Patent • Fibrosis

Hope for patients with a fatal disease: Pacific Therapeutics developing fibrosis treatments (Vantage Wire) - Anticipated regulatory approval for PTL-202 in IPF in the US, Europe, & other countries within the next two years

Anticipated EU regulatory • Anticipated FDA event • Anticipated non-US regulatory • Fibrosis

Pacific Therapeutics annonuces non-brokered financing (The Wall Street Journal) - "The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction which are $1 billion plus market opportunities....The Company will offer up to 8,000,000 Units at a price of $0.05 per Unit for aggregate proceeds of CAD $400,000 (the "Offering")."

Financing • Fibrosis

Pacific Therapeutics Ltd. announces United States issuance of patent for treating fibrosis (StockHouse) - "The Company is pleased to announce that the United States Patent Office (USPO) has issued United States Patent No. 9029385 for the Company's patent application, Compositions and Methods for Treating Fibroproliferative Disorders."

Patent • Fibrosis

Efficacy of Granulocyte Colony Stimulating Factor and N-acetyl Cysteine Therapies in Patients with Severe Alcoholic Hepatitis. (PubMed, Clin Gastroenterol Hepatol) - P4; "In a pilot randomized controlled trial, we found administration of GCSF to improve liver function and increase survival times in patients with severe AH, compared to standard therapy. We found no evidence for benefit of adding NAC to GCSF. These findings require confirmation in larger trials. ClincialTrials.gov no: NCT02971306."

Journal

Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy. (PubMed, Neuroimmunomodulation) - "In this review, the studies were classified into 2 major groups: (1) clinical research whose authors classify therapies with primary anti-inflammatory and immunomodulatory actions, making use of: sulforaphane, celecoxib, lenalidomide, pentoxifylline, spironolactone, flavonoid luteolin, corticosteroids, oral immunoglobulin, intravenous immunoglobulin, cell therapy, dialyzable lymphocyte extracts, minocycline, and pioglitazone; and (2) other ASD therapies already used or currently under study whose initial characteristics were neither anti-inflammatory nor immunomodulatory initially, but displayed a capacity for immunomodulation throughout the treatment: risperidone, vitamin D, omega-3, Ginkgo biloba, L-carnosine, N-acetylcysteine, and microbiome restoration. These studies used various data acquisition methodologies. Questions arose such the need for randomized and placebo-controlled studies with greater numbers of participants as well as the use of biomarkers to refine..."

Biomarker • Journal • Review